New Board Members Join Kerecis

Reykjavik / Isafjordur, Iceland, June 17, 2013 – Kerecis Limited, the emerging tissue-regeneration company, today announced that Andri Sveinsson and Kristjan Johannesson have been appointed to the company's board of directors.

Sveinsson, a partner at Novator Partners LLP in London, has extensive experience in banking and corporate finance. He has held board positions in listed and unlisted companies in several sectors, among these the generic pharmaceutical company Actavis.

Johannesson is an Isafjordur, Iceland-based professional. He is the chairman of Hradfrystihusid-Gunnvor hf., one of the largest companies in the Icelandic fish industry.

Comment:
Gudmundur Fertram Sigurjonsson, Executive Chairman, Kerecis Limited: 
"We welcome the new board members, whose skills and experience are particularly appropriate at this time in our development. Sveinsson has extensive corporate finance experience, and Johannesson strengthens our relationship with Icelandic investors as well as with the Icelandic manufacturing industry."

About Kerecis
Kerecis (http://www.kerecis.com) is a development and manufacturing company that produces a novel, patent-pending, tissue-regeneration material derived from fish skin to accelerate the healing of wounds and tissue reconstruction. The Kerecis material addresses the large, so-far-unmet need of the double-digit-growth biologics segment of the chronic-wounds, hernia-repair and dermatology markets. 

Development programs involve the creation of regenerative technologies for repairing damaged tissue in vivo, as well as growing the tissues and organs in vitro and implanting them into the patient at a later stage. The Kerecis material offers advantages over existing human- and porcine-derived products, including improved manufacturing economics and a lower risk of disease transfer. Since it is derived from fish, the material is both kosher and halal compatible, eliminating cultural and religious constraints to usage, with equivalent or better clinical performance than alternative approaches. For more information, e-mail: [email protected] or call 703-879-6535 (U.S.) or +354-8494960 (Iceland).

###

For further information, contact:
G. Fertram Sigurjonsson, Executive Chairman, Kerecis Limited
Phone (Iceland) +354-8494960 / (U.S.) 703-879-6535
E-mail: [email protected]

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.